> >Register Now <<

Speaker: Roscoe Brady, PhD, MD

In this presentation we will review the use of TMS for treating symptoms of schizophrenia as well as its use as a research tool to understand schizophrenia pathophysiology. We will discuss symptoms such as medication refractory hallucinations, negative symptoms, and cognitive dysfunction. We will review different approaches including targets derived from both structural and functional neuroanatomy. Finally, we will talk about future directions in treatment including the use of TMS for schizophrenia related comorbidity.

Key learning objectives include:

• Summarize the history of TMS trials for medication resistant symptoms of schizophrenia.
• Describe how TMS is used as a research tool for understanding schizophrenia pathology.
• Describe future directions for TMS trials both for treating schizophrenia symptoms as well as schizophrenia related comorbidity.

One CME credit is available.  CE Language

Take advantage of our live Q&A session at the conclusion of the webinar.

*Registered attendees will receive access to the on-demand video recording by Friday, February 6, 2026. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.

When:

USA - February 3, 2026 at 8:00pm ET | 5:00pm PT
UK- February 4, 2026 at 1:00am GMT
Australia- February 4, 2026 at 12:00pm AEDT

Cost:

Member: $25
Trainee Member: FREE
Non-Member: $50

> >Register Now <<

About the Speaker

Roscoe Brady
Roscoe Brady MD, PhD is a board-certified psychiatrist and neuroscientist. He is the Vice-Chair for Research in the Department of Psychiatry at Beth Israel Deaconess Medical Center and an Associate Professor at Harvard Medical School. He is also the director of the Research Concentration in the Beth Israel Deaconess Medical Center Harvard Psychiatry Residency Training Program. He is the recipient of the Jonathan F. Borus Outstanding Early Educator Award and Stuart T. Hauser Mentorship Award from Harvard Medical School. His research focus is developing neuromodulation treatments for medication resistant symptoms of psychotic disorders. He is the Principal Investigator of multiple NIMH R01 funded clinical trials.